Form 4: Arcus Biosciences Director Lacey Granted Stock Options and Restricted Stock Units

Director David L. Lacey of Arcus Biosciences received stock options and restricted stock units (RSUs) on June 6, 2024, according to a Form 4 filing with the SEC.

Summary

• On June 6, 2024, David L. Lacey, a director of Arcus Biosciences, Inc. (RCUS), was granted 8,400 restricted stock units (RSUs) and options to purchase 24,000 shares of common stock.
• The RSUs vest fully on the earlier of June 6, 2025, or the next annual meeting of stockholders, and will fully vest upon a change in control of the company.
• The stock options, with an exercise price of $15.90, also vest fully on the earlier of June 6, 2025, or the next annual meeting of stockholders, and will become fully vested and exercisable upon a change in control.
• Following these transactions, Lacey beneficially owns 57,652 shares of Arcus Biosciences common stock and options to purchase 24,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity to a director is a standard practice and aligns interests with shareholders. The vesting terms are typical and don't raise any immediate concerns.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting acceleration upon a change in control may incentivize the director to consider opportunities that benefit shareholders.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting terms of the RSUs and stock options suggest a focus on long-term value creation and alignment with shareholder interests.

Industry Context

Stock option and RSU grants are common compensation practices in the biotechnology industry to incentivize and retain key personnel. The vesting terms, including acceleration upon a change in control, are also typical.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used by companies like Gilead, Amgen, and Regeneron.
• The vesting schedules, typically over 1-4 years, are in line with industry norms to incentivize long-term performance.
• Change-in-control provisions are also common, ensuring executives are aligned with shareholder interests during potential acquisition scenarios.

Stakeholder Impact

• Shareholders: The grant of equity aligns the director's interests with those of the shareholders.
• Employees: The equity grants can contribute to a positive work environment by aligning incentives across the company.

Key Dates